Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan

被引:117
作者
Miyachi, Hideyuki
Miki, Ikuya
Aoyama, Nobuo
Shirasaka, Daisuke
Matsumoto, Yuko
Toyoda, Masanori
Mitani, Toshifumi
Morita, Yoshinori
Tamura, Takao
Kinoshita, Shohiro
Okano, Yoshie
Kumagai, Shunichi
Kasuga, Masato
机构
[1] Kobe Univ, Grad Sch Med, Dept Endoscopy, Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis, Kobe, Hyogo 6500017, Japan
[3] Kobe Univ, Grad Sch Med, Dept Med Bioinformat, Div Clin Pathol & Immunol, Kobe, Hyogo 6500017, Japan
[4] Kobe Univ, Sch Med, Clin Lab, Kobe, Hyogo 6500017, Japan
[5] Kobe Univ Hosp, Kobe, Hyogo, Japan
关键词
Levofloxacin; gyrA; QRDR;
D O I
10.1111/j.1523-5378.2006.00415.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Recent years have witnessed a decrease in the rate of Helicobacter pylori eradication due to antimicrobial resistance, clarithromycin or metronidazole resistance in particular. As one of the alternatives to the standard regimens, levofloxacin-containing therapy has been considered a promising regimen. Nevertheless, there is a little information concerning the prevalence of levofloxacin resistance and this resistance mechanism. Materials and Methods: Levofloxacin susceptibility was examined using E-test in 507 H. pylori strains clinically isolated in Japan from 2001 to 2004. Mutation patterns in the quinolone resistance-determining regions of the gyrA and gyrB genes were evaluated, performing direct sequencing of 68 levofloxacin-resistant and 50 susceptible strains. Results: Primary levofloxacin resistance was found in 76 (15.0%) strains. Fifty-seven (83.8%) of 68 levofloxacin-resistant strains analyzed had point mutations in gyrA at Asn-87 or Asp-91, while seven (14.0%) of 50 susceptible strains had gyrA mutations. There was a significant difference in the occurrence of gyrA mutations between levofloxacin-resistant and -susceptible strains (p < .001). In levofloxacin-resistant strains, the occurrence of gyrA mutations at Asn-87 was most common regardless of minimal inhibitory concentration levels, and that of gyrA mutations at Asp-91 tended to be associated with low-level resistance. A double gyrA mutation at Asn-87 and Asp-91 might have an additional impact. As for gyrB, three (4.4%) of 68 levofloxacin-resistant strains with no susceptible strains had mutations. Conclusions: Primary levofloxacin resistance was common in Japan and primarily related to gyrA mutations at Asn-87 and Asp-91.
引用
收藏
页码:243 / 249
页数:7
相关论文
共 39 条
[1]   Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori [J].
Alm, RA ;
Ling, LSL ;
Moir, DT ;
King, BL ;
Brown, ED ;
Doig, PC ;
Smith, DR ;
Noonan, B ;
Guild, BC ;
deJonge, BL ;
Carmel, G ;
Tummino, PJ ;
Caruso, A ;
Uria-Nickelsen, M ;
Mills, DM ;
Ives, C ;
Gibson, R ;
Merberg, D ;
Mills, SD ;
Jiang, Q ;
Taylor, DE ;
Vovis, GF ;
Trost, TJ .
NATURE, 1999, 397 (6715) :176-180
[2]   Interaction between DNA gyrase and quinolones:: Effects of alanine mutations at GyrA subunit residues Ser83 and Asp87 [J].
Barnard, FM ;
Maxwell, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (07) :1994-2000
[3]   Helicobacter pylori uptake and efflux:: Basis for intrinsic susceptibility to antibiotics in vitro [J].
Bina, JE ;
Alm, RA ;
Uria-Nickelsen, M ;
Thomas, SR ;
Trust, TJ ;
Hancock, REW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :248-254
[4]   Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria [J].
Boyanova, L ;
Stancheva, I ;
Spassova, Z ;
Katzarov, N ;
Mitov, I ;
Koumanova, R .
JOURNAL OF MEDICAL MICROBIOLOGY, 2000, 49 (05) :415-418
[5]   High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy [J].
Branca, G ;
Spanu, T ;
Cammarota, G ;
Schito, AM ;
Gasbarrini, A ;
Gasbarrini, GB ;
Fadda, G .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 (05) :433-438
[6]   Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999) [J].
Cabrita, J ;
Oleastro, M ;
Matos, R ;
Manhente, A ;
Cabral, J ;
Barros, R ;
Lopes, AI ;
Ramalho, P ;
Neves, BC ;
Guerreiro, AS .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (06) :1029-1031
[7]   Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection [J].
Cammarota, G ;
Cianci, R ;
Cannizzaro, O ;
Cuoco, L ;
Pirozzi, G ;
Gasbarrini, A ;
Armuzzi, A ;
Zocco, MA ;
Santarelli, L ;
Arancio, F ;
Gasbarrini, G .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (10) :1339-1343
[8]   Mutations in Helicobacter pylori rdxA gene sequences may not contribute to metronidazole resistance [J].
Chisholm, SA ;
Owen, RJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (04) :995-999
[9]   New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures:: a pilot study [J].
Coelho, LGV ;
Moretzsohn, LD ;
Vieira, WLS ;
Gallo, MA ;
Passos, MCF ;
Cindr, JM ;
Cerqueira, MC ;
Vitiello, L ;
Ribeiro, ML ;
Mendonça, S ;
Pedrazzoli, J ;
Castro, LP .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (06) :783-787
[10]   Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands [J].
Debets-Ossenkopp, YJ ;
Herscheid, AJ ;
Pot, RGJ ;
Kuipers, EJ ;
Kusters, JG ;
Vandenbroucke-Grauls, CMJE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (04) :511-515